Vaccinex Inc (NASDAQ: VCNX) recently issued an update to its shareholders stating that the American Association for Cancer and research meetings chose to speak during the event. The Association chose it due to its contributions to the first stage of the KEYNOTE-B84 study.
Details of the presentation
Vaccinex research was to evaluate if mixing the drug with other compounds such as the pembrolizumab could help treat patients with experiences of the recurring neck and head cancer. The Association will conduct the meetings in New Orleans from the 8th April 2022 to 13th April 2022.
Terrence Fisher, the V.P. of Clinical Science, will give the presentation on behalf of the company. Moreover, the presentation will be in New Orleans, the U.S, on April 11.
The company possesses the backing up and creation rights in various businesses, including pepinemab and others. Vaccinex is also a prominent investor in various researches, including the KEYNOTE-884 research that landed it the award from the Association. The company has also executed partnerships with various institutions such as Dohme Corp and others.
The institution is the first to create a distinct and alternative approach to obtaining treatments for various neurodegenerative illnesses, including Cancer. Vaccinex developed a distinct and effective drug known as pepinemab that alters the functions of SEMA4D. SEMA4D is an effective compound that fights off the immune system’s penetrating and assists in fighting the tumor.
Pepinemab inhibits the tumor’s ability to protect itself
The drug is among the company’s best creations as it is an IgG4 that halts the decreases and fights the production of SEMA4D. In turn, the low production self-control the tumor’s ability to defend itself as SEMA4D is responsible for the immunity of the tumor.
Pepinemab also works by infiltrating dendritic cells, thus reversing the tumor’s immunosuppressive effect on the body.
In 2020, the company presented results from a study investigating the effect of combining Pepinemab with BAVENCIO. Furthermore, Vaccinex highlighted these results in July 2021. Findings from the Phase 1b/2 indicated that patients who had PD-L1 low tumors responded better to the combinations than with either drug. In addition, Pepinemab increased BAVENCIO’s ability to penetrate cytotoxic T cells.
